JPH09502862A - 結合特異性を有する組換ジスルフィド安定化ポリペプチドフラグメント - Google Patents
結合特異性を有する組換ジスルフィド安定化ポリペプチドフラグメントInfo
- Publication number
- JPH09502862A JPH09502862A JP7502172A JP50217295A JPH09502862A JP H09502862 A JPH09502862 A JP H09502862A JP 7502172 A JP7502172 A JP 7502172A JP 50217295 A JP50217295 A JP 50217295A JP H09502862 A JPH09502862 A JP H09502862A
- Authority
- JP
- Japan
- Prior art keywords
- variable region
- polypeptide
- cysteine
- nucleic acid
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.リガンドに特異的に結合するポリペプチドであって、リガンド結合成分の 第一可変領域を含んで成り、この第一可変領域がこのリガンド結合成分の第二の 別の可変領域にジスルフィド結合を介して結合しており、この結合がこの第一可 変領域と第二可変領域のフレームワーク領域を連結している、前記ポリペプチド 。 2.前記ポリペプチドが抗体の定常領域を実質的に含まない、請求項1記載の ポリペプチド。 3.前記ポリペプチドがラジオアイソトープ、酵素、毒素、キレート化剤又は 薬剤にコンジュゲートされている、請求項1記載のポリペプチド。 4.前記ポリペプチドが毒素、酵素又はその他の薬剤に組換的に融合されてい る、請求項1記載のポリペプチド。 5.前記第一可変領域が 98,99,100又は 101位においてシステインを含み、 そして前記第二可変領域が43,44,45,46又は47位においてシステインを含み、 かかる位置はKabat and Wuにより公開された番号付け系に従って決定されたもの であり、抗体の軽鎖及び重鎖に各々が相当する、請求項1記載のポリペプチド。 6.前記第一可変領域が100位においてシステインを含み、そして前記第二可 変領域が44位においてシステインを含む、請求項5記載のポリペプチド。 7.前記第一可変領域が42,43,44,45又は46位においてシステインを含み、 そして前記第二可変領域が 103,104,105又は 106位においてシステインを含み 、かかる位置はKabat and Wuにより公開された番号付け系に従って決定されたも のであり、抗体の軽鎖及び重鎖に各々が相当する、請求項1記載のポリペプチド 。 8.前記第一可変領域が43位においてシステインを含み、そして前記第二可変 領域が 105位においてシステインを含む、請求項7記載のポリペプチド。 9.前記第一可変領域が抗体の軽鎖可変領域(VL)であり、そして前記第二 可変領域が抗体の重鎖可変領域(VH)である、請求項1記載のポリペプチド。 10.前記第一可変領域がT細胞レセプターのα可変鎖領域であり、そして前記 第二可変領域がT細胞レセプターのβ可変鎖領域である、請求項1記載のポリペ プチド。 11.リガンドに特異的に結合するポリペプチドを製造する方法であって、ここ でこのポリペプチドはリガンド結合成分の第一可変領域を含んで成り、この第一 可変領域はこのリガンド結合成分の第二可変領域に、これら2つの可変領域のフ レームワーク領域におけるジスルフィド結合を介して連結されており、ここでこ の方法は: (a)この第一可変領域に関する核酸を、42,43,44,45又は46位においてシ ステインをコードするように突然変異させ、そしてこの第二可変領域に関する核 酸を、103,104,105又は 106位においてシステインをコードするように突然変 異させる、ここでかかる位置はKabat and Wuにより公開された番号付け法に従い 、抗体の軽鎖及び重鎖領域のそれぞれに対応して決定されたものである;又は (b)この第一可変領域に関する核酸を、43,44,45,46又は47位においてシ ステインをコードするように突然変異させ、そしてこの第二可変領域に関する核 酸を、98,99,100又は 101位においてシステインをコードするように突然変異 させる、ここでかかる位置はKabat and Wuにより公開された番号付け法に従い、 抗体の軽鎖又は重鎖のそれぞれに対応して決定されたものである;次いで (c)発現系においてこの第一可変領域に関する核酸及びこの第 二可変領域に関する核酸を発現させる;そして (d)抗原に対する結合親和性を有する前記ポリペプチドを回収する; ことを含んで成る、方法。 12.前記方法が前記ポリペプチドを精製することを更に含んで成る、請求項11 記載の方法。 13.請求項1記載のポリペプチドをコードする核酸。 14.毒素又は薬剤をコードする核酸を更に含む、請求項13記載の核酸。 15.前記ポリペプチドに毒素もしくは薬剤又は毒性配列がペプチドリンカーに よって連結されている、請求項14記載の核酸。 16.前記第一可変領域及び前記第二可変領域がそれぞれMAb B3のVH及びVLに 由来する、請求項1記載のポリペプチド。 17.前記VH領域の44位のアルギニン及び前記VL領域の 100位のセリンがシス テインにより置き換えられており、ここでかかる位置はKabat and Wuにより公開 された番号付け系に従って決定されたものである、請求項16記載のポリペプチド 。 18.前記VH領域の 105位のグルタミン及び前記VL領域の43位のセリンがシス テインに置き換えられており、ここでかかる位置はKabat and Wuにより公開され た番号付け系に従って決定されたものである、請求項16記載のポリペプチド。 19.前記VH領域の95位のセリンがチロシンに置き換えられている、請求項17 記載のポリペプチド。 20.前記VH領域の95位のセリンがチロシンに置き換えられている、請求項16 記載のポリペプチド。 21.抗体の軽鎖可変領域(VL)をコードする核酸配列であって、ここでこの VLは 42,43,44,45,46,98,99,100又は 101位 においてシステインを含んでおり、かかる位置はKabat and Wuにより公開された 番号付け系に従って決定されたものである、前記核酸。 22.前記VLの 100位においてシステインをコードする、請求項21記載の核酸 。 23.前記VLの43位においてシステインをコードする、請求項21記載の核酸。 24.抗体の重鎖可変領域(VH)をコードする核酸配列であって、ここでこの VHは 43,44,45,46,47,103,104,105又は 106位においてシステインを含 んでおり、かかる位置はKabat and Wuにより公開された番号付け系に従って決定 されたものである、前記核酸。 25.前記VLの44位においてシステインをコードする、請求項24記載の核酸。 26.前記VLの 105位においてシステインをコードする、請求項22記載の核酸 。 27.腫瘍細胞の増殖を阻害するための薬理組成物であって、MAb B3に由来する 42,43,44,45,46,98,99又は 100位においてシステインを含む軽鎖可変領域 (VL)と、MAb B3に由来する 43,44,45,46,47,103,104,105又は 106位 においてシステインを含む重鎖可変領域(VH)とを有する、腫瘍細胞に特異的 に結合するポリペプチドを含んで成り、ここでこのVLとVHとはジスルフィド結 合を介して連結されており、そして更にこのポリペプチドが毒素をも含んで成る 、前記組成物。 28.前記VLとVHとがペプチドリンカーにより更に連結されている、請求項9 記載のポリペプチド。 29.前記第一可変領域及び前記第二可変領域が各々 MAb e23のVL 及びVHに由来する、請求項1記載のポリペプチド。 30.前記α可変領域が41,42,43,44,45,106,107,108又は 109位におい てシステインを含み、そして前記β可変領域が108,109,110,111,41,42,43 ,44又は45位においてシステインを含み、かかる位置はKabat and Wuにより公開 された番号付け系により決定されたものであり、そしてT細胞レセプターのα及 びβ可変鎖領域に相当するものである、請求項10記載のポリペプチド。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/077,252 | 1993-06-14 | ||
US08/077,252 US5747654A (en) | 1993-06-14 | 1993-06-14 | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
PCT/US1994/006687 WO1994029350A2 (en) | 1993-06-14 | 1994-06-14 | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09502862A true JPH09502862A (ja) | 1997-03-25 |
JP3474574B2 JP3474574B2 (ja) | 2003-12-08 |
Family
ID=22136984
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50217295A Expired - Lifetime JP3474574B2 (ja) | 1993-06-14 | 1994-06-14 | 結合特異性を有する組換ジスルフィド安定化ポリペプチドフラグメント |
Country Status (10)
Country | Link |
---|---|
US (3) | US5747654A (ja) |
EP (1) | EP0703926B1 (ja) |
JP (1) | JP3474574B2 (ja) |
AT (1) | ATE169932T1 (ja) |
AU (1) | AU682705B2 (ja) |
CA (1) | CA2164984C (ja) |
DE (1) | DE69412614T2 (ja) |
DK (1) | DK0703926T3 (ja) |
ES (1) | ES2124419T3 (ja) |
WO (1) | WO1994029350A2 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013505923A (ja) * | 2009-09-25 | 2013-02-21 | ユセベ ファルマ ソシエテ アノニム | ジスルフィドで安定化された多価抗体 |
WO2014069647A1 (ja) * | 2012-11-05 | 2014-05-08 | 全薬工業株式会社 | 抗体又は抗体組成物の製造方法 |
JP2021525786A (ja) * | 2018-06-04 | 2021-09-27 | ディアテーバ ソチエタ レスポンサビリタ リミタータ | 抗cd99ダイアボディ又はigg抗体及びそれらの使用 |
Families Citing this family (147)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4425115A1 (de) * | 1994-07-15 | 1996-01-18 | Boehringer Mannheim Gmbh | Verfahren zur Modifizierung der Stabilität von Antikörpern |
JPH11513669A (ja) * | 1995-10-13 | 1999-11-24 | アメリカ合衆国 | ジスルフィド安定化抗体フラグメントを含む免疫毒素 |
US5986065A (en) | 1997-03-10 | 1999-11-16 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
US7541034B1 (en) | 1997-03-20 | 2009-06-02 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors |
DE19721700C1 (de) * | 1997-05-23 | 1998-11-19 | Deutsches Krebsforsch | Mutierter OKT3-Antikörper |
US6809184B1 (en) * | 1997-12-01 | 2004-10-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
US6519003B1 (en) | 1998-03-26 | 2003-02-11 | Eastman Kodak Company | Camera with combination four-way directional and mode control interface |
ATE403154T1 (de) * | 1999-04-13 | 2008-08-15 | Wilex Ag | Diagnostischer und therapeutischer einsatz von antikörpern gegen den urokinase-rezeptor |
CA2374398C (en) | 1999-05-27 | 2011-03-15 | Ira Pastan | Immunoconjugates having high binding affinity |
WO2000075162A1 (en) * | 1999-06-07 | 2000-12-14 | Mirus Corporation | A compound containing a labile disulfide bond |
EP1074563A1 (en) * | 1999-08-02 | 2001-02-07 | F. Hoffmann-La Roche Ag | Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof |
US7118745B1 (en) | 1999-09-27 | 2006-10-10 | The Regents Of The University Of California | Engineering antibodies that bind irreversibly |
CA2385888A1 (en) * | 1999-09-27 | 2001-04-05 | The Regents Of The University Of California | Engineering antibodies that bind irreversibly |
EP1282722B1 (en) * | 1999-10-15 | 2011-06-15 | Avatar Medical, L.L.C. | Stabilized proteins |
US6492498B1 (en) | 1999-11-15 | 2002-12-10 | Regents Of The University Of Minnesota | Multimeric immunotoxins |
JP4439808B2 (ja) | 2000-06-05 | 2010-03-24 | アルター・バイオサイエンス・コーポレーション | T細胞レセプター融合体および結合体ならびにそれらの使用方法 |
US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
DE10105912A1 (de) * | 2001-02-09 | 2002-08-14 | Roche Diagnostics Gmbh | Rekombinante Proteinase K |
JP2005512161A (ja) * | 2001-03-12 | 2005-04-28 | ボード オブ レジェンツ,ザ ユニバーシティー オブ テキサス システム | ペプチドおよびタンパク質の立体配座アンサンブルの列挙およびリガンド親和性分析のためのコンピュータベースのストラテジー |
US20030118585A1 (en) * | 2001-10-17 | 2003-06-26 | Agy Therapeutics | Use of protein biomolecular targets in the treatment and visualization of brain tumors |
DE60234193D1 (de) * | 2001-06-14 | 2009-12-10 | Scripps Research Inst | Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen |
ES2239246T3 (es) | 2001-08-31 | 2005-09-16 | Avidex Limited | Receptor soluble de celulas t. |
AU2003209886A1 (en) * | 2002-03-14 | 2003-09-22 | Qlt Inc. | Cancer associated araf1 protein kinase and its uses |
EP1561759B9 (en) * | 2002-10-11 | 2009-08-26 | Chugai Seiyaku Kabushiki Kaisha | Cell death-inducing agent |
US20040101929A1 (en) * | 2002-11-22 | 2004-05-27 | Chi-Yao Chang | Expressing mammalian protein complexes in fish |
US7820787B2 (en) * | 2003-01-23 | 2010-10-26 | The Regents Of The University Of California | Multi-functional antibodies |
GB0304068D0 (en) * | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
ATE532793T1 (de) * | 2003-07-03 | 2011-11-15 | Avatar Biotechnologies Inc | Verfahren zur herstellung von molekülen mit verminderter immunogenität |
US7754209B2 (en) * | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
ATE468356T1 (de) | 2003-11-25 | 2010-06-15 | Us Gov Health & Human Serv | Mutierte anti-cd22-antikörper und immunkonjugate |
GB0328363D0 (en) | 2003-12-06 | 2004-01-14 | Imp College Innovations Ltd | Therapeutically useful molecules |
EP1710255A4 (en) * | 2003-12-12 | 2008-09-24 | Chugai Pharmaceutical Co Ltd | MODIFIED ANTIBODIES RECOGNIZING A TRIMER OR LARGER RECEPTOR |
WO2005056603A1 (ja) * | 2003-12-12 | 2005-06-23 | Chugai Seiyaku Kabushiki Kaisha | 細胞死誘導剤 |
WO2005056602A1 (ja) * | 2003-12-12 | 2005-06-23 | Chugai Seiyaku Kabushiki Kaisha | アゴニスト活性を有する改変抗体のスクリーニング方法 |
US7247443B2 (en) * | 2004-03-17 | 2007-07-24 | University Of Hawaii | Sensor constructs and detection methods |
JP4799405B2 (ja) * | 2004-04-09 | 2011-10-26 | 中外製薬株式会社 | 細胞死誘導剤 |
ATE475669T1 (de) * | 2004-06-29 | 2010-08-15 | Immunocore Ltd | Einen modifizierten t-zellen-rezeptor exprimierende zellen |
WO2006106903A1 (ja) * | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | sc(Fv)2構造異性体 |
EP1927367A4 (en) * | 2005-05-18 | 2009-08-12 | Univ Tokushima | NOVEL PHARMACEUTICAL AGENT BASED ON AN ANTI-HLA ANTIBODY |
JP5085322B2 (ja) | 2005-06-10 | 2012-11-28 | 中外製薬株式会社 | sc(Fv)2を含有する医薬組成物 |
CA2610987C (en) * | 2005-06-10 | 2013-09-10 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
PT2298815E (pt) | 2005-07-25 | 2015-07-16 | Emergent Product Dev Seattle | Moléculas de ligaçao especificas para cd37 e especificas para cd20 |
EP2311854B1 (en) | 2005-07-29 | 2013-04-17 | The Government of the United States of America, as represented by the Secretary of Health and Human Services | Mutated pseudomonas exotoxins with reduced antigenicity |
JP5374359B2 (ja) * | 2006-03-17 | 2013-12-25 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 安定化されたポリペプチド化合物 |
CA3149553C (en) | 2006-06-12 | 2023-11-21 | Aptevo Research And Development Llc | Single-chain multivalent binding proteins with effector function |
MX2009000487A (es) * | 2006-07-13 | 2009-01-27 | Chugai Pharmaceutical Co Ltd | Inductor de muerte celular. |
CL2008000719A1 (es) * | 2007-03-12 | 2008-09-05 | Univ Tokushima Chugai Seiyaku | Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a |
EP2388266B1 (en) | 2007-05-11 | 2014-04-23 | Altor BioScience Corporation | Fusion molecules and IL-15 variants |
DK2197903T3 (en) * | 2007-09-04 | 2015-01-05 | Us Gov Health & Human Serv | Deletions in Domain II from Pseudomonas exotoxin A that reduce non-specific TOXICITY |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
CA2719924C (en) * | 2008-04-11 | 2017-10-03 | Philip Tan | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
WO2010112194A1 (en) | 2009-04-02 | 2010-10-07 | F. Hoffmann-La Roche Ag | Antigen-binding polypeptides and multispecific antibodies comprising them |
JP5501439B2 (ja) * | 2009-04-02 | 2014-05-21 | ロシュ グリクアート アクチェンゲゼルシャフト | 完全長抗体と単鎖Fabフラグメントとを含む多重特異的抗体 |
MX2011010166A (es) | 2009-04-07 | 2011-10-11 | Roche Glycart Ag | Anticuerpos biespecificos anti-erbb-3/anti-c-met. |
JP5616428B2 (ja) | 2009-04-07 | 2014-10-29 | ロシュ グリクアート アクチェンゲゼルシャフト | 三価の二重特異性抗体 |
BRPI1014449A2 (pt) | 2009-04-07 | 2017-06-27 | Roche Glycart Ag | anticorpos biespecíficos anti-erbb-2/ anti-c-met. |
EP2435473B1 (en) | 2009-05-27 | 2013-10-02 | F.Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
WO2011003780A1 (en) | 2009-07-06 | 2011-01-13 | F. Hoffmann-La Roche Ag | Bi-specific digoxigenin binding antibodies |
WO2011031441A1 (en) | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
WO2011030107A1 (en) | 2009-09-10 | 2011-03-17 | Ucb Pharma S.A. | Multivalent antibodies |
JP5795765B2 (ja) | 2009-09-11 | 2015-10-14 | アメリカ合衆国 | 低減した免疫原性を有する改良型シュードモナス(Pseudomonas)外毒素A |
EP4134095A1 (en) | 2009-09-15 | 2023-02-15 | The Board of Trustees of the Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
WO2011034605A2 (en) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
GB0920127D0 (en) * | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
WO2011100455A1 (en) | 2010-02-12 | 2011-08-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Inhibition of antibody responses to foreign proteins |
GB201005064D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
BR112013002167A2 (pt) | 2010-08-24 | 2016-05-31 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação |
WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
AU2011305476B2 (en) | 2010-09-21 | 2016-12-01 | Altor Bioscience Corporation | Multimeric IL-15 soluble fusion molecules and methods of making and using same |
US11053299B2 (en) | 2010-09-21 | 2021-07-06 | Immunity Bio, Inc. | Superkine |
EP2654790B1 (en) | 2010-12-22 | 2019-02-06 | Teva Pharmaceuticals Australia Pty Ltd | Modified antibody with improved half-life |
JP5766296B2 (ja) | 2010-12-23 | 2015-08-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用 |
MX342034B (es) | 2011-02-28 | 2016-09-12 | Hoffmann La Roche | Proteinas monovalentes que se unen a antigenos. |
RU2607038C2 (ru) | 2011-02-28 | 2017-01-10 | Ф. Хоффманн-Ля Рош Аг | Антигенсвязывающие белки |
US9624291B2 (en) | 2011-03-17 | 2017-04-18 | Ramot At Tel-Aviv University Ltd. | Bi- and monospecific, asymmetric antibodies and methods of generating the same |
EP2502934B1 (en) * | 2011-03-24 | 2018-01-17 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | Single chain antigen recognizing constructs (scARCs) stabilized by the introduction of novel disulfide bonds |
KR20140036216A (ko) | 2011-05-06 | 2014-03-25 | 더 거번먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 레프리젠티드 바이 더 세크러터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 | 메소텔린을 표적화하는 재조합 면역독소 |
AU2012268013B2 (en) | 2011-06-09 | 2016-11-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pseudomonas exotoxin A with less immunogenic T cell and/or B cell epitopes |
US9206240B2 (en) | 2011-09-16 | 2015-12-08 | The United States of America, as represented by the Secretary, Department of Helath and Human Services | Pseudomonas exotoxin A with less immunogenic B cell epitopes |
MX2014009565A (es) | 2012-02-10 | 2014-11-10 | Genentech Inc | Anticuerpos monocatenarios y otros heteromultimeros. |
WO2014001325A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
ES2597228T3 (es) | 2012-06-27 | 2017-01-17 | F. Hoffmann-La Roche Ag | Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas |
WO2014009465A1 (en) | 2012-07-13 | 2014-01-16 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
US9671405B2 (en) | 2012-09-19 | 2017-06-06 | Cornell University | Identifying taxane sensitivity in prostate cancer patients |
WO2014108854A1 (en) | 2013-01-09 | 2014-07-17 | Fusimab Ltd. | Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies |
CA2904806C (en) | 2013-04-29 | 2021-11-23 | F. Hoffmann-La Roche Ag | Human fcrn-binding modified antibodies and methods of use |
EP2992010B1 (en) | 2013-04-29 | 2021-03-24 | F.Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
WO2014205187A1 (en) | 2013-06-20 | 2014-12-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cytolethal distending toxin subunit b conjugated or fused to bacillus anthracis toxin lethal factor |
EP3027649B1 (en) | 2013-08-01 | 2020-04-01 | F.Hoffmann-La Roche Ag | Tnfa-il-17 bispecific antibodies |
CA2926215A1 (en) | 2013-10-06 | 2015-04-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modified pseudomonas exotoxin a |
BR112016006929A2 (pt) | 2013-10-11 | 2017-09-19 | Hoffmann La Roche | Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo |
CN105873953A (zh) | 2013-11-04 | 2016-08-17 | 格兰马克药品股份有限公司 | 重靶向t细胞的异源二聚免疫球蛋白的产生 |
WO2015073878A1 (en) | 2013-11-15 | 2015-05-21 | Ur Diet, Llc | Real-time satiety biofeedback |
CN111057151B (zh) | 2014-01-06 | 2022-05-03 | 豪夫迈·罗氏有限公司 | 单价血脑屏障穿梭模块 |
EP3553087A1 (en) | 2014-01-08 | 2019-10-16 | The Board of Trustees of the Leland Stanford Junior University | Targeted therapy for lung cancer |
US9738702B2 (en) | 2014-03-14 | 2017-08-22 | Janssen Biotech, Inc. | Antibodies with improved half-life in ferrets |
EP3126389A1 (en) | 2014-04-02 | 2017-02-08 | F. Hoffmann-La Roche AG | Method for detecting multispecific antibody light chain mispairing |
CA2945816A1 (en) | 2014-04-15 | 2015-10-22 | University Of Virginia Patent Foundation | Isolated t cell receptors and methods of use therefor |
ES2899890T3 (es) | 2014-06-30 | 2022-03-15 | Altor Bioscience Corp | Moléculas basadas en IL-15 y métodos de uso de las mismas |
JP2017520575A (ja) | 2014-07-01 | 2017-07-27 | ファイザー・インク | 二重特異的ヘテロ二量体ダイアボディおよびその使用 |
ES2847203T3 (es) | 2014-08-01 | 2021-08-02 | The Board Of Supervisors Of Louisiana State Univ And Agricultural And Mechanical College | Detección y tratamiento de herpesvirus bovino |
PL3215528T3 (pl) | 2014-11-06 | 2020-01-31 | F.Hoffmann-La Roche Ag | Warianty regionu Fc ze zmodyfikowanym wiązaniem FcRn i sposoby stosowania |
PL3227332T3 (pl) | 2014-12-03 | 2020-06-15 | F. Hoffmann-La Roche Ag | Wielospecyficzne przeciwciała |
AU2016258115A1 (en) | 2015-05-06 | 2017-11-23 | Janssen Biotech, Inc. | Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof |
UA126278C2 (uk) | 2015-09-21 | 2022-09-14 | Аптево Рісьорч Енд Девелопмент Ллс | Поліпептиди, які зв'язують cd3 |
SI3356411T1 (sl) | 2015-10-02 | 2021-09-30 | F. Hoffmann-La Roche Ag | Bispecifična protitelesa, specifična za PD1 in TIM3 |
WO2017055399A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Cellular based fret assay for the determination of simultaneous binding |
US11340219B2 (en) | 2016-03-17 | 2022-05-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-pY1235-MET immunological binding reagent |
US10865230B2 (en) | 2016-05-27 | 2020-12-15 | Altor Bioscience, Llc | Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains |
KR20190091264A (ko) | 2016-10-21 | 2019-08-05 | 알토 바이오사이언스 코포레이션 | 다량체 il-15 기반 분자 |
AU2018213718B2 (en) | 2017-01-26 | 2022-08-25 | Zlip Holding Limited | CD47 antigen binding unit and uses thereof |
AU2018231170B2 (en) | 2017-03-06 | 2020-07-16 | Altor Bioscience Corporation | IL-15-based fusions to IL-12 and IL-18 |
US20190048055A1 (en) | 2017-03-31 | 2019-02-14 | Altor Bioscience Corporation | Alt-803 in combination with anti-cd38 antibody for cancer therapies |
IL268527B2 (en) | 2017-04-05 | 2024-03-01 | Hoffmann La Roche | Bispecific antibodies bind to PD1 and LAG3 specifically |
KR20200090742A (ko) | 2017-08-28 | 2020-07-29 | 알토 바이오사이언스 엘엘씨 | Il-7 및 il-21에의 il-15 기반 융합 |
JP7145895B2 (ja) | 2017-09-01 | 2022-10-03 | 四川科倫博泰生物医薬股▲フン▼有限公司 | 組換え二重特異性抗体 |
CA3089333C (en) | 2018-03-26 | 2023-10-10 | Altor Bioscience Llc | Anti-pdl1, il-15 and tgf-beta receptor combination molecules |
PE20210320A1 (es) | 2018-06-01 | 2021-02-16 | Novartis Ag | Moleculas de union contra bcma y usos de las mismas |
US20220275043A1 (en) | 2018-07-17 | 2022-09-01 | Massachusetts Institute Of Technology | Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof |
CN109053895B (zh) | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
KR20220004979A (ko) | 2019-03-27 | 2022-01-12 | 유엠씨 우트레크트 홀딩 비.브이. | 조작된 iga 항체 및 사용 방법 |
US20210139585A1 (en) | 2019-05-21 | 2021-05-13 | Novartis Ag | Cd19 binding molecules and uses thereof |
CA3140142A1 (en) | 2019-05-21 | 2020-11-26 | Novartis Ag | Trispecific binding molecules against bcma and uses thereof |
WO2020236797A1 (en) | 2019-05-21 | 2020-11-26 | Novartis Ag | Variant cd58 domains and uses thereof |
AU2020334237A1 (en) | 2019-08-19 | 2022-02-10 | Universität Basel | Cell therapy methods |
CA3162748A1 (en) | 2019-11-25 | 2021-06-03 | Akeso Biopharma, Inc. | Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof |
EP4077363A1 (en) | 2019-12-20 | 2022-10-26 | F. Hoffmann-La Roche AG | Il-37 fusion proteins and uses thereof |
US20230128499A1 (en) | 2020-03-27 | 2023-04-27 | Novartis Ag | Bispecific combination therapy for treating proliferative diseases and autoimmune diseases |
JP2023548529A (ja) | 2020-11-06 | 2023-11-17 | ノバルティス アーゲー | Cd19結合分子及びその使用 |
EP4240494A1 (en) | 2020-11-06 | 2023-09-13 | Novartis AG | Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies |
CN112500491B (zh) | 2020-12-18 | 2022-04-08 | 深圳市迈加瑞生物技术有限公司 | 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途 |
AU2022206061A1 (en) | 2021-01-06 | 2023-07-06 | F. Hoffmann-La Roche Ag | Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody |
CN115068603A (zh) | 2021-03-12 | 2022-09-20 | 中山康方生物医药有限公司 | 含有抗pd-1-抗vegfa双特异性抗体的药物组合及其用途 |
CN115192718A (zh) | 2021-04-14 | 2022-10-18 | 中山康方生物医药有限公司 | 抗cd47的单克隆抗体及其用途 |
WO2023279092A2 (en) | 2021-07-02 | 2023-01-05 | Genentech, Inc. | Methods and compositions for treating cancer |
KR20240038008A (ko) | 2021-07-28 | 2024-03-22 | 에프. 호프만-라 로슈 아게 | 암 치료 방법 및 조성물 |
CN114181310B (zh) | 2022-02-14 | 2022-07-05 | 中山康方生物医药有限公司 | 抗tigit抗体、其药物组合物及用途 |
WO2023194807A2 (en) * | 2022-04-04 | 2023-10-12 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
CA3208473A1 (en) | 2022-06-22 | 2023-12-22 | Akeso Biopharma, Inc. | Pharmaceutical composition and use thereof |
WO2024077118A2 (en) | 2022-10-06 | 2024-04-11 | Bicara Therapeutics Inc. | Multispecific proteins and related methods |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5132405A (en) * | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5091513A (en) * | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
JP3105898B2 (ja) * | 1988-04-16 | 2000-11-06 | セルテック リミテッド | 組換えdnaタンパクの製造方法 |
EP0861893A3 (en) * | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
CA2120153C (en) * | 1991-09-30 | 2006-06-06 | Ira Pastan | Recombinant immunotoxins |
-
1993
- 1993-06-14 US US08/077,252 patent/US5747654A/en not_active Expired - Lifetime
-
1994
- 1994-06-14 JP JP50217295A patent/JP3474574B2/ja not_active Expired - Lifetime
- 1994-06-14 DK DK94921956T patent/DK0703926T3/da active
- 1994-06-14 WO PCT/US1994/006687 patent/WO1994029350A2/en active IP Right Grant
- 1994-06-14 ES ES94921956T patent/ES2124419T3/es not_active Expired - Lifetime
- 1994-06-14 AU AU72464/94A patent/AU682705B2/en not_active Expired
- 1994-06-14 EP EP94921956A patent/EP0703926B1/en not_active Expired - Lifetime
- 1994-06-14 DE DE69412614T patent/DE69412614T2/de not_active Expired - Lifetime
- 1994-06-14 AT AT94921956T patent/ATE169932T1/de active
- 1994-06-14 CA CA002164984A patent/CA2164984C/en not_active Expired - Lifetime
-
1998
- 1998-01-05 US US09/002,753 patent/US6147203A/en not_active Expired - Lifetime
-
2000
- 2000-09-07 US US09/657,274 patent/US6558672B1/en not_active Expired - Lifetime
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013505923A (ja) * | 2009-09-25 | 2013-02-21 | ユセベ ファルマ ソシエテ アノニム | ジスルフィドで安定化された多価抗体 |
WO2014069647A1 (ja) * | 2012-11-05 | 2014-05-08 | 全薬工業株式会社 | 抗体又は抗体組成物の製造方法 |
JPWO2014069647A1 (ja) * | 2012-11-05 | 2016-09-08 | 全薬工業株式会社 | 抗体又は抗体組成物の製造方法 |
US10344099B2 (en) | 2012-11-05 | 2019-07-09 | Zenyaku Kogyo Kabushikikaisha | Antibody and antibody composition production method |
JP2021525786A (ja) * | 2018-06-04 | 2021-09-27 | ディアテーバ ソチエタ レスポンサビリタ リミタータ | 抗cd99ダイアボディ又はigg抗体及びそれらの使用 |
Also Published As
Publication number | Publication date |
---|---|
US6147203A (en) | 2000-11-14 |
CA2164984A1 (en) | 1994-12-22 |
AU682705B2 (en) | 1997-10-16 |
AU7246494A (en) | 1995-01-03 |
DE69412614T2 (de) | 1998-12-24 |
US5747654A (en) | 1998-05-05 |
DE69412614D1 (de) | 1998-09-24 |
ATE169932T1 (de) | 1998-09-15 |
US6558672B1 (en) | 2003-05-06 |
ES2124419T3 (es) | 1999-02-01 |
DK0703926T3 (da) | 1999-05-25 |
WO1994029350A3 (en) | 1995-02-02 |
EP0703926A1 (en) | 1996-04-03 |
JP3474574B2 (ja) | 2003-12-08 |
CA2164984C (en) | 2009-02-17 |
EP0703926B1 (en) | 1998-08-19 |
WO1994029350A2 (en) | 1994-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09502862A (ja) | 結合特異性を有する組換ジスルフィド安定化ポリペプチドフラグメント | |
AU706056B2 (en) | Immunotoxin containing a disulfide-stabilized antibody fragment | |
US7355012B2 (en) | Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells | |
US7081518B1 (en) | Anti-mesothelin antibodies having high binding affinity | |
Reiter et al. | Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins. | |
Brinkmann et al. | A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. | |
US7456260B2 (en) | Humanized antibody | |
US7982011B2 (en) | Mutated anti-cd22 antibodies and immunoconjugates | |
US5608039A (en) | Single chain B3 antibody fusion proteins and their uses | |
ES2659039T3 (es) | Exotoxinas de pseudomonas mutadas con antigenicidad reducida | |
Better et al. | Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab'and F (ab') 2. | |
US6287562B1 (en) | Methods of inhibiting the growth of cells bearing LewisY antigens using B1, B3, or B5 targeted immunoconjugates | |
Jung et al. | Design of interchain disulfide bonds in the framework region of the Fv fragment of the monoclonal antibody B3 | |
JP2018524296A (ja) | Cd123抗体及びその複合体 | |
Bera et al. | A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2 | |
Brinkmann et al. | Recombinant immunotoxins containing the VH or VL domain of monoclonal antibody B3 fused to Pseudomonas exotoxin. | |
Brinkmann et al. | Stabilization of a recombinant Fv fragment bybase-loop interconnection and VH-VL permutation | |
Benhar et al. | Rapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3 (Fv)-PE38. | |
AU717611B2 (en) | Tumor-specific antibody fragments, fusion proteins, and uses thereof | |
EP4289863A1 (en) | Bispecific antibody targeting il-17a and il-36r and application thereof | |
JPH10508202A (ja) | 腫瘍特異性抗体断片、融合タンパク質、およびそれらの使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080919 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090919 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100919 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110919 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110919 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120919 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130919 Year of fee payment: 10 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |